Previous studies have shown that f12 microglobulin (fl2m) is associated with glycoproteins present on the envelope of urinary human cytomegalovirus (CMV). flzm is non-covalently associated with the ~ chain of human leukocyte antigen (HLA) class I antigens and therefore it was of interest to determine whether the class I c~ chain is also associated with the fl2m-CMV complex. Using a panel of monoclonal antibodies recognizing different conformational determinants on the HLA class l heterodimer or free fl2m, we have shown that flzm but not the ~ chain of HLA class I could be immunoprecipitated from 125I-surfacelabelled virions purified directly from urine. We therefore conclude that host class I HLA ~ chains are not associated with fl2m on the envelope of urinary CMV.
Introduction
Previous work from this laboratory has demonstrated that host f12 microglobulin (fl2m) is associated with the envelope of cytomegalovirus (CMV) purified directly from human urine . Furthermore, a laboratory strain of CMV, AD 169, was shown to bind fl2m in vitro after the virus was released from infected cells . fl2m forms the light chain of the class I human leukocyte antigen (HLA) heterodimer which is present in the cytoplasm and on the membranes of all nucleated cells, flzm is also found in free form in body fluids such as urine and blood (Berggard & Beam, 1968) and we have previously suggested that in vivo CMV binds fl2m from body fluids after release of the virus from cells . This suggestion was supported by the finding that extracellular CMV strain AD 169 propagated in vitro bound fl2m after addition of the virus to normal human urine . However, body fluids also contain soluble class I HLA molecules (Vincent et al., 1976; Vincent & Revellard, 1979) and it is possible that in vivo CMV might bind the soluble class I HLA heterodimer as well as free fl2m. In addition, CMV acquires its envelope by budding through host cell membranes which may potentially contain class I HLA molecules (Severi et al., 1988) . Therefore, the virus may acquire fl2m together with the class I HLA ~ chain from these membranes as part of the virus envelope. The purpose of the present t Present address: National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar EN6 3QG, U.K. study, therefore, was to use a panel of monoclonal antibodies (MAbs) with specificity for various determinants on free fl2m, and the class I HLA heterodimer to determine whether the ct chain of the host class I HLA heterodimer is associated with the CMV-fl2m complexes.
Methods
Purification of MAbs. Hybridomas secreting the murine MAbs BBM.1, L368, BB7.7, BB7.5, W632 and PA2.6 were obtained from the American Type Culture Collection. The C21 hybridoma was a gift from Dr A. R. Sanderson. The irrelevant MAb used in this study, RF6, recognizing hepatitis B surface antigen, was a gift from Dr A. Goodall. Ascitic fluid was harvested from tumour-bearing mice and the IgG was purified using Protein A-Sepharose (Pharmacia) according to the manufacturer's instructions.
Biotinylation of MAbs. Affinity-purified MAbs or purified nonimmune mouse IgG (Sigma) were adjusted to a concentration of 1 mg/ml in 0-1 M-NaHCO3 and reacted for4 h at ambient temperature with N-hydroxysuccinimidobiotin (1 mg/ml, Sigma) in DMSO (Sigma), at a ratio of 120 ~tl per mg antibody. The antibody mixture was then dialysed overnight against PBS at 4 °C, to remove any unbound biotin, and stored at 4 °C in 0-1 ~ sodium azide prior to use. To check that equivalent biotinylation of antibodies had been achieved, they were titrated in an ELISA system using streptavidin peroxidase (Serotec) or anti-mouse IgG peroxidase (Serotec). All antibodies were found to be biotinylated to an equivalent extent.
Purification of CMVfrom urine. Urine known to contain CMV by virus isolation was clarified at 7000g for 15min. It was then concentrated firstly using an Amicon spiral wound ultrafiltration cartridge with an Mr cutoff of 30K, followed by a stirred cell concentrator (Amicon) with an Mr cutoffof 100K. Concentrated urine was centrifuged at 110000g for 45 rain at 4 °C through a two-step potassium tartrate/glycerol, negative viscosity :positive density gradient (modified from Talbot & Almeida, 1977) . The diffuse band at the 0001-0282 © 1992 SGM interface representing virions was harvested and washed with PBS (300000 g, 30 rain, 4 °C). The virion pellet was resuspended in PBS, immediately divided into aliquots and stored at -7 0 °C prior to use.
lodination o f C M V or fl2m. Virions purified from urine (20 to 100 p.g), or fl2m (100 lag; Serotec), were diluted to a total volume of 100 lal with PBS. lodination was performed using the iodogen method (Fraker & Speck, 1978) with 37 MBq Na~2SI (IMS 30, Amersham). Unreacted iodine was removed by gel filtration through a PD10 column (Pharmacia).
Solubilization of I 25 I-labelled CM V envelope proteins.
Radioiodinated CMV envelope proteins were extracted with 10 mi-Tris-HCl, 1 mM-CaCI, 0.15-M-NaCI, 1 ~ (v/v) Triton X-100, 1 ~ (v/v) aprotinin, 2 mM-PMSF and l ~ (v/v) ethanol. The extract was left on ice for 15 rain and then centrifuged for 5 min in a microcentrifuge (MSE).
In vivo labelling of Raji cells with [3H]leucine.
Raji cells (1-6 × 10V/ml, 5 nal; Flow Laboratories) were incubated for 1 h at 37 °C in leucine-free Eagle's MEM with Earle's salts (Gibco) supplemented with Ultroser G (2~ v/v, Gibco), antibiotics and glutamine (L-MEM). Cells were pelleted at 500g for 6 min and incubated for 4 h at 37 °C in L-MEM (4 ml) containing [3H]leucine (22.2 MBq, TRK 170; Amersham) and then washed twice in PBS.
Preparation of Raft cell extracts.
Metabolically labelled Raji cells (8 × 107 cells) were resuspended in 1 ml digitonin (10 laM in 0.02 M-Tris-HCl pH 7.4) and left on ice for 5 min. Cell extracts were pelleted in a microcentrifuge for 5 rain, washed once in PBS and solubilized in 900111 20 mM-Tris-HCl pH 9, 137 mi-NaC1, 1 mM-CaClz, 0.5 ml~-MgCI2, 10~ (v/v) glycerol, 1 ~ (v/v) NP40 and 1 ~ (v/v) aprotinin for 15 rain on ice. Remaining cell debris was removed by further centrifugation and the clear supernatant containing the solubilized proteins was stored at -20 °C prior to use.
Immunoprecipitation. All incubations were carried out in microcentrifuge tubes at ambient temperature on a rotating wheel. Solubilized i z51. labelled envelope proteins (approximately 3 MBq), 125I-f12m (approximately 0.4 MBq) or metabolically labelled Raji cell proteins (8 x 107 cells) were precleared for 1 h by the addition of 600 lag biotinylated nonimmune mouse IgG and non-specific complexes were removed by a further 1 h incubation with 300 lal streptavidin-agarose (BRL). The precleared supernatant was then incubated for 1 h with 50 ~tg of the appropriate biotinylated anti-HLA class I or anti-fl2m MAb and specific immune complexes were collected after a 1 h incubation with 40 lal streptavidin-agarose. Immunoprecipitates were then sequentially washed (5 x 5 min) with wash buffer containing 0.5 u-Tris-HCl, 0.1 M-NaCI, 1 ~ (v/v) Triton X-100 and 1 ~ (w/v) SDS pH 7.3, reducing the detergent concentration by 50~ in each subsequent wash. Immune complexes were eluted by boiling in gel sample buffer containing SDS (4% w/v) and 2-mercaptoethanol (1-2% v/v) and subjected to electrophoresis through 8 to 16~ gradient polyacrylamide gels according to Laemmli (1970) . After staining the gels with Coomassie blue [0.25~ in methanol (40~ v/v):acetic acid (10% v/v)] they were dried and exposed at -7 0 °C to Hyperfdm MP (Amersham) with intensifying screens for Iz5I gels. Equivalent amounts of the various antibodies were collected in immunoprecipitations as determined by the visualization of immunoglobulin bands on gels of the immunoprecipitates. 
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Results
Ability of the panel o f antibodies to immunoprecipitate fl2m or class I HLA ~ chain
A panel of monoclonal anti-HLA antibodies was used to determine whether CMV purified directly from human urine had the ct chain of class I HLA as well as f12 m bound to the viral envelope. The reported specificity of the antibodies used in this study was confirmed in immunoprecipitation experiments using solubilized extracts from Raji cells which had been metabolically labelled with [3H]leucine. Immunoprecipitations were performed using biotinylated antibodies and streptavidin-agarose as the affinity matrix. The antibody C21 immunoprecipitated fiE m alone, whereas antibodies BBM.1, BB7.7, BB7.5, PA2.6 and W6/32 immunoprecipitated both the 45K ~ chain and fiE m (Fig. 1) , although their relative amounts varied. In particular, W6/32 immunoprecipitated less fl2m than the other antibodies. The antibody L368 displayed the same reactivity pattern as BBM.1 (data not shown). No proteins were immunoprecipitated from solubilized cell extract preparations by the irrelevant antibody RF6 or by streptavidin-agarose alone (Fig. 1) .
The reactivity of the panel of antibodies with free f12 m was also determined and the results are shown in Fig. 2 . Antibodies L368, BBM. l, C21, BB7.7, and to a lesser extent BB7.5, immunoprecipitated free fl2m whereas W6/32, PA2.6 and RF6 did not.
Reactivity of the antibody panel with urinary C M V
The ability of the panel of antibodies to immunoprecipitate fl2m or class I HLA ~ chain from purified urinary . The antibodies used were (a) L368, BBM. l, C21 and W6/32 (lanes 2 to 5, respectively). Lanes 6 and 7 contain immunoprecipitates using the irrelevant antibody RF6 and streptavidin-agarose alone respectively. (b) BBT. 5, BB7.7 and PA2.6 (lanes 2 to 4, respectively). Lane 5 contains an immunoprecipitate obtained using streptavidin-agarose alone. The radiolabelled CMV protein preparation used for the immunoprecipitation is shown in lanes 8 and 6 of (a) and (b), respectively.
CMV was determined using a preparation of solubilized 125I-labelled envelope proteins. The results are shown in Fig. 3 . Antibodies L368, BBM. 1, C21, BB7.7 and BB7.5 immunoprecipitated fl2m from urinary CMV although the relative amount of fl2m was less with BB7.5 than with the other antibodies. Neither W6/32 nor PA2.6 immunoprecipitated a protein of 45K as expected for the class I HLA 0t chain. The irrelevant antibody and streptavidin-agarose alone did not immunoprecipitate any labelled proteins (Fig. 3 ).
Discussion
The antibodies used in the present study may be classified into four groups. These are based on their reported reactivity with the class I HLA heterodimer and the ability of free fl2m or free soluble class I HLA to inhibit antibody binding to the cell surface. Antibody C21 is characteristic of group A antibodies which recognize free fl2m but not the flzm-class I HLA ~ chain complex (Liabeuf et al., 1981) . We have confirmed the lack of reactivity of C21 with cell surface class I HLA by flow cytometry (data not shown). Antibodies in groups B, C and D all recognize the class I heterodimer on the cell surface; however, fl2m is able to inhibit this binding to differing extents. Group B antibodies L368 (Lampson et al., 1983) and BBM.1 (Brodsky & Parham, 1982) recognize epitopes on fl2m since their binding to cells is strongly inhibited by free fl2m. It has been shown that the arginine residue at position 45 of the fl2m molecule is important for recognition by BBM. 1 (Parham et al., 1983) . Group C antibodies BB7.5 and BB7.7 are presumed to be directed towards conformational antigens on the heterodimer predominantly on the B2m subunit. Their binding to cells is only weakly inhibited by free fl2m but strongly inhibited by soluble class I HLA (Brodsky & Parham, 1982) . Finally group D antibodies W6/32 and PA2.6 (Brodsky & Parham, 1982) are reported to recognize predominantly ~ chain determinants of the heterodimer, the conformation of which is dependent on the presence of bound fl2m. The binding of these antibodies to cells is not affected by free fl2m (Brodsky & Parham, 1982) . The use of this panel of MAbs in immunoprecipitation studies with free B2m or cell extracts containing fl2m and the class I HLA heterodimer yielded results consistent with the expected pattern, with the possible exception of the group C antibodies. The results are summarized in Table 1 . It can be seen that both of the group C antibodies reacted with free fl2m in immunoprecipitation experiments even though fl2m was only reported to inhibit weakly the binding of these antibodies to the cell surface (Brodsky & Parham, 1982) . It should be noted --+ * The binding of the antibodies in groups B to D to the cell surface is inhibited by soluble class I HLA molecules (Brodsky and Parham, 1982) ; only the binding of the group B antibodies, and to a much lesser extent the group C antibodies, is inhibited by free fl2m (Brodsky & Parham, 1982) . The antibody C21 is not reactive with cell surface class I HLA (Liabeuf et aL, 1981) . t + +, Strong reactivity; +, weak reactivity; -, no reactivity. :~ Data not shown in this study but can be found in Lampson et al. (1983) .
that biotinylated antibodies and streptavidin-agarose were used for the immunoprecipitation experiments (rather than Protein A) in order to overcome the problem of the different affinities of antibodies of different IgG subclasses for Protein A. It also avoided interference from human IgG which is present on the surface of CMV purified from body fluids (Rose et al., 1990) and which binds to Protein A.
The reactivity of the antibody groups with urinary CMV is also summarized in Table 1 . It can be seen that all antibodies in groups A, B and C immunoprecipitated fl2m from urinary CMV whereas those in group D failed to do so. Thus, all the antibodies that reacted with free fl2m reacted with CMV-associated fl2m, and those which reacted only with the class I HLA heterodimer (group D) did not immunoprecipitate fl:m from CMV. This result strongly suggests that fl2m and not the class I HLA heterodimer is associated with the envelope of urinary CMV. Those antibodies which react with fl2m either in free form or as part of the class I HLA heterodimer (groups B and C) do not coprecipitate an ~ chain from CMV together with the fl2m. However, under similar conditions both chains of the class I HLA heterodimer could be immunoprecipitated from Raji cell membranes, demonstrating that the fl2m on urinary CMV is not associated with host class I HLA ~ chain.
These findings support our previous view that in vivo CMV binds free fl2m present in body fluids after its release from cells and does not acquire it as a result of budding through host cell membanes containing class I HLA molecules. These results also suggest that CMV does not bind soluble class I HLA molecules from urine. It is not clear whether this is due to differences in the concentrations of free fl2m and soluble class I HLA molecules in this body fluid, to the state of class I HLA molecules in urine or to the fact that CMV may not be able to bind fl2m when it is already bound to the class I HLA ct chain. Little is known about the origin or state of soluble class I HLA molecules in body fluids such as urine; they could represent secreted forms of class I HLA, derived from alternative splicing and consequent deletion of the transmembrane exon of the molecule or alternatively they may represent proteolytically cleaved fragments of cell surface molecules.
Under the conditions used in this study none of the antibodies which immunoprecipitated flEm from CMV coprecipitated other labelled proteins. We conclude that the affinity of binding of fl2m for CMV is considerably weaker than that of the MAbs for fl2m.
The failure of W6/32 to recognize any protein associated with the envelope of urinary CMV suggests that not only is there no classical host class I HLA A, B or C locus product on CMV, but that the closely related products of the HLA-E, F and G loci are also absent, since this antibody reacts with heterodimers of fl2m and the 7 chains of these molecules (Shimizu et al., 1988) . In addition, none of the MAbs used coprecipitated fl2m with any protein from CMV which could represent the product of the HLA-like gene H-301 (now called UL18) identified in the genome of CMV strain AD169 (Beck & Barrell, 1988) and proposed by these authors to be the fl2m-binding protein of CMV. Yet one of the antibodies used here, BBM.1, was found to immunoprecipitate both fl2m and the UL18 gene product from lysates of cells co-infected with recombinant vaccinia viruses carrying the UL18 and fl2m genes (Browne et al., 1990) . Thus we conclude that either the UL18 gene product is not associated with fie m on urinary CMV virions, or that such binding is different in some way from that observed in the cells infected with the recombinant vaccinia viruses, so that the complex is not recognized by the antibody BBM. 1. However our finding here that BBM. 1 and four other antibodies can immunoprecipitate fiE m from urinary CMV virions perhaps argues against the latter possibility, although as mentioned above it may be that the affinity of binding between fiE m and the antibodies may be greater than that between f12 m and viral proteins.
It is of interest that group A antibody C21, which recognizes free but not class I HLA ~ chain-bound fie m, immunoprecipitated fl2m from CMV. This indicates that the determinant recognized by this antibody, which is concealed when f12 m binds to the 0t chain, is exposed when fl2m binds to CMV, suggesting that CMV binds to fl2m in a manner dissimilar to that of the class I HLA 0t chain. It is worthy of note in this regard that other studies from this laboratory using molecular modelling techniques have predicted that if the UL18 gene product is responsible for the binding of fl2m to CMV, such binding would not be expected to be in an HLA-like manner (Tysoe-Calnon et al., 1991) . However, since all antibodies which recognized free fiE m also immunoprecipitated free fl2m from CMV, we cannot discount the possibility that, even under the mild conditions of solubilization used, the fie m had dissociated from the virus after purification. The procedure used for the purification of urinary CMV does not allow the copurification of free fl2m, as demonstrated by the fact that when free fl2m was added to herpes simplex virus before purification, it could not be demonstrated in the virus preparation after purification .
In conclusion, we have demonstrated that five MAbs against free or class I HLA ~ chain-bound fie m could immunoprecipitate fl2m from the envelope of urinary CMV. However, they did not coprecipitate the class I HLA ~ chain. Two additional antibodies specific for the class I HLA heterodimer failed to immunoprecipitate either f12 m or the class I HLA c~ chain from urinary CMV. We conclude that CMV isolated from urine has host fl2m but not host class I HLA ~ chain associated with the viral envelope.
